Cancer

17 results.

October 20, 2021 American Cancer Society grant to support Van Andel Institute research into anti-cancer medications

GRAND RAPIDS, Mich. (Oct. 20, 2021) — Van Andel Institute’s Scott Rothbart, Ph.D., has earned a four-year, $792,000 Research…

October 20, 2021 Meet the scientist behind the science: Dr. Scott Rothbart

Earlier today, we announced that Van Andel Institute Associate Professor Dr. Scott Rothbart has been awarded a Research Scholar Grant from…

September 22, 2021 Coriell Institute for Medical Research, Van Andel Institute awarded estimated $12.4 million SPORE grant from National Cancer Institute

Estimated at $12.4 million, this five-year grant supports a nationwide team of researchers investigating epigenetic therapies for cancer

The Coriell Institute for Medical Research and…

August 18, 2021 Van Andel Institute earns prestigious grant to train postdoctoral fellows in cancer epigenetics

GRAND RAPIDS, Mich. (Aug. 18, 2021) — The National Cancer Institute has awarded Van Andel Institute a five-year, $1.7 million grant to establish a…

April 4, 2019 Blocking epigenetic “Swiss army knife” may be a new strategy for treating colorectal cancer

GRAND RAPIDS, Mich. (April 4, 2019) — A new study out today in Cancer Cell shows that blocking specific regions of a protein called…

November 28, 2018 High-throughput platform enables scientists to map activity of an emerging class of cancer drug targets

GRAND RAPIDS, Mich. (Nov. 28, 2018) — A powerful new biochemical platform is fueling the study of a family of enzymes that are promising targets for…

September 13, 2018 Revealing the root causes of colon cancer: Three questions for Dr. Ali Lanctot Chomiak

Although the overall prevalence of colon cancer has steadily dropped since the 1980s, a close look at the data from recent years reveals a disturbing…

February 3, 2017 In their own words: The most exciting advances in cancer research

In honor of World Cancer Day on Saturday, we asked our scientists and collaborators a simple question—what do you think is…